Cryo-Cell International (NYSEAMERICAN:CCEL) Stock Passes Below 200 Day Moving Average – Time to Sell?

Cryo-Cell International Inc. (NYSEAMERICAN:CCEL)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.86 and traded as low as $2.72. Cryo-Cell International shares last traded at $2.97, with a volume of 14,239 shares trading hands.

Cryo-Cell International Price Performance

The firm’s 50 day moving average price is $3.29 and its 200-day moving average price is $3.85. The stock has a market cap of $26.68 million, a P/E ratio of -10.68 and a beta of 0.55.

Cryo-Cell International (NYSEAMERICAN:CCEL) last posted its quarterly earnings results on Friday, February 27th. The company reported ($0.47) EPS for the quarter. The firm had revenue of $7.84 million for the quarter.

Institutional Trading of Cryo-Cell International

An institutional investor recently bought a new position in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new stake in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned approximately 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is currently owned by institutional investors and hedge funds.

Cryo-Cell International Company Profile

Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.

The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.